Can a new injection tame severe asthma?

NCT ID NCT07746687

Not yet recruiting Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial is testing an experimental drug called JNJ-95597528 in adults with moderate to severe asthma that is not well controlled by current treatments. The goal is to see if the drug can reduce the number of asthma attacks over 48 weeks compared to a placebo. Participants will receive either the drug or a placebo as a subcutaneous injection, and researchers will monitor lung function and symptom changes. The study aims to determine whether this new approach could offer a better way to manage asthma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-95597528, an experimental drug given as a subcutaneous injection
What this could lead to: If successful, this could lead to a new treatment option that reduces asthma attacks and improves symptom control for people with moderate to severe asthma.
What could go wrong: This is an early-stage trial, so the drug may not prove more effective than placebo. Possible side effects are not yet fully known, and results may not apply to all asthma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.